We are live on ! Find out more
SOPH icon

SOPHiA GENETICS

7.63 USD
-0.34
4.27%
At close Updated Oct 30, 4:00 PM EDT
Pre-market
After hours
7.63
0.00
0%
1 day
-4.27%
5 days
3.11%
1 month
-8.95%
3 months
32.47%
6 months
46.17%
Year to date
63.38%
1 year
47.01%
5 years
-45.5%
10 years
-54.47%
 

About: Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Employees: 415

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 22.2%
Neutral 77.8%
Negative 0%
Neutral
PRNewsWire
11 days ago
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026
BOSTON and ROLLE, Switzerland, Oct. 20, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2026 before U.S. markets open on Tuesday, November 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026
Neutral
GlobeNewsWire
23 days ago
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Neutral
PRNewsWire
23 days ago
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Positive
Zacks Investment Research
1 month ago
SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
Neutral
MarketBeat
2 months ago
When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
The volume of shares traded in a session often gets a passing mention in the financial press until a stock experiences unusually high volume. That's because volume can provide an important measure of the conviction behind a stock's price movement.
When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
Neutral
Seeking Alpha
2 months ago
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
Positive
MarketBeat
2 months ago
SOPHiA GENETICS Q2 Earnings Call Highlights
SOPHiA GENETICS NASDAQ: SOPH reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements.
SOPHiA GENETICS Q2 Earnings Call Highlights
Neutral
PRNewsWire
2 months ago
SOPHiA GENETICS Reports Second Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue was $23.3 million, up 27% year-over-year Gross margin was 64.6% on a reported basis and 72.1% on an adjusted basis, compared to 67.0% reported and 74.4% adjusted in the prior year period Net loss was $22.4 million, flat year-over-year; Adjusted EBITDA loss was $8.8 million, improving 27% year-over-year The company is raising 2026 revenue guidance to a range of $94 million to $96 million, representing 22% to 24% year-over-year growth.
SOPHiA GENETICS Reports Second Quarter 2026 Results
Neutral
PRNewsWire
2 months ago
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN). This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies.
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
Neutral
PRNewsWire
3 months ago
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets open on Tuesday, August 4, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
Price charts implemented using Lightweight Charts™